Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 249 entries
View as:

Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03923179 Org: User:
Start: 04/19/19 End: 12/31/21 Due: 12/31/22

A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02301481 Org: User:
Start: 01/31/14 End: 12/31/17 Due: 12/31/18

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05546255 Org: User:
Start: 06/01/20 End: 12/31/23 Due: 12/31/24

Factors Influencing Cancer Patients Participation in Clinical Trials in China.

Phase: N/A Priority: Normal
NCT ID: NCT03412344 Org: User:
Start: 07/15/17 End: 12/31/18 Due: 12/31/19

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03854617 Org: User:
Start: 02/20/19 End: 12/20/25 Due: 12/20/26

S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02947061 Org: User:
Start: 04/30/15 End: 04/30/19 Due: 04/30/20

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05154396 Org: User:
Start: 01/01/22 End: 12/31/24 Due: 12/31/25

The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains

Phase: N/A Priority: Normal
NCT ID: NCT01048190 Org: User:
Start: 08/31/08 End: 03/31/09 Due: 03/31/10

Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02370849 Org: User:
Start: 10/31/09 End: 02/28/15 Due: 02/28/16

Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02654106 Org: User:
Start: 10/31/11 End: 11/30/15 Due: 11/30/16

Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）

Phase: N/A Priority: Normal
NCT ID: NCT02218437 Org: User:
Start: 10/31/13 End: 10/31/15 Due: 10/31/16

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT03296410 Org: User:
Start: 09/14/17 End: 09/02/19 Due: 09/02/20

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04620837 Org: User:
Start: 11/01/20 End: 12/31/23 Due: 12/31/24

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT04683198 Org: User:
Start: 04/01/21 End: 06/30/24 Due: 06/30/25

Endoscopic Ultrasound Predict the Sensitivity of Stage II / III Rectal Cancer Preoperative Concurrent Chemoradiotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01582750 Org: User:
Start: 10/31/10 End: 12/31/15 Due: 12/31/16

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT02646735 Org: User:
Start: 12/31/15 End: 12/31/20 Due: 12/31/21

How do Super Lean Subjects Keep Resistant to Body Weight Gain?

Phase: N/A Priority: Normal
NCT ID: NCT03221322 Org: User:
Start: 04/06/17 End: 12/31/25 Due: 12/31/26

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02496949 Org: User:
Start: 11/30/11 End: 08/31/13 Due: 08/31/14

Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02533271 Org: User:
Start: 08/31/15 End: 08/31/25 Due: 08/31/26

Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT02510378 Org: User:
Start: 01/31/14 End: 12/31/22 Due: 12/31/23

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05016869 Org: User:
Start: 04/12/22 End: 08/31/24 Due: 08/31/25

Low-dose Radiotherapy in iNHL

Phase: N/A Priority: Normal
NCT ID: NCT05543070 Org: User:
Start: 05/01/22 End: 01/01/25 Due: 01/01/26

A Comparison of the Ambu®AuraGain™ and the Laryngeal Mask Airway Supreme™ in Normal Airway Patients

Phase: N/A Priority: Normal
NCT ID: NCT03108391 Org: User:
Start: 01/01/17 End: 10/31/17 Due: 10/31/18

Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01871363 Org: User:
Start: 10/31/12 End: - Due: -

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02041338 Org: User:
Start: 01/31/14 End: 12/31/17 Due: 12/31/18